Lantheus Medical Imaging of North Billerica, MA, has completed patient enrollment for a multicenter phase IV observational study to evaluate the use of ultrasound imaging agents in routine clinical practice, the company said.
The study, CaRES (Contrast Echocardiography REgistry for Safety Surveillance), includes 1,060 patients enrolled at 15 sites in the U.S. who required the use of Lantheus' Definity ultrasound contrast agent for echocardiography due to a previous suboptimal echocardiogram. The study will gather and analyze data on patient demographics and characteristics, reasons for using Definity, results of safety monitoring, and the nature and frequency of any adverse events, Lantheus said.
Related Reading
Lantheus signs Mo-99 supply deal, May 20, 2009
Moly crisis leads to price hike for Lantheus technetium generators, May 15, 2009
Lantheus buys Epix's MS-325 rights, April 7, 2009
ACC study: Lantheus PET tracer shows promise, April 1, 2009
ACC study documents echo contrast safety in critically ill patients, March 31, 2009
Copyright © 2009 AuntMinnie.com
